{"id":48166,"date":"2022-09-09T15:01:52","date_gmt":"2022-09-09T13:01:52","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/medx-health-confirms-further-interim-closing-and-application-for-further-extension-of-price-protection-for-private-placement-convertible-loan-note-financing\/"},"modified":"2022-09-09T15:01:52","modified_gmt":"2022-09-09T13:01:52","slug":"medx-health-confirms-further-interim-closing-and-application-for-further-extension-of-price-protection-for-private-placement-convertible-loan-note-financing","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/medx-health-confirms-further-interim-closing-and-application-for-further-extension-of-price-protection-for-private-placement-convertible-loan-note-financing\/","title":{"rendered":"MedX Health Confirms Further Interim Closing and Application for Further Extension of Price Protection for Private Placement Convertible Loan Note Financing"},"content":{"rendered":"
\n

MISSISSAUGA, Ontario–(BUSINESS WIRE)–$MDX<\/a> #SkinCancer<\/a>–MedX Health Corp. (\u201cMedX<\/b>\u201d or the \u201cCompany<\/b>\u201d) (TSXV: MDX) is pleased to announce that, in connection with the Private Placement (the \u201cFinancing<\/b>\u201d), and further to the $250,000 first tranche closing of which was announced in its Press Release dated July 14, 2022, and its Press Release dated August 11, 2022 announcing application for extension of Price Protection, it has closed on further subscriptions for $350,000, for issuance of seven more Convertible Notes. No Cash Commissions or Agent\u2019s Warrants were paid or issued in relation to those seven Convertible Notes. Securities issued on are subject to a four month restriction from trading in accordance with relevant regulatory and stock exchange policies. The Company also has further subscriptions in hand for $500,000 which are in process of being funded, and additional subscriptions are anticipated.\n<\/p>\n

<\/a><\/p>\n

\nThe Company also announces that it has applied to the TSX Venture Exchange for a final extension of a further 30 days price protection in order to complete subscriptions for up to a total of $4 million. Further Closings will be subject to receipt of subscriptions and a number of other conditions, including, without limitation, the receipt of all relevant regulatory and Stock Exchange approvals or acceptances.\n<\/p>\n

\nThe Financing is a non-brokered Private Placement to accredited investors of up to $4 million by issuance of up to 80 Convertible Loan Notes, each with a face value of $50,000 (\u201cConvertible Notes<\/b>\u201d), the terms of which are fully described in the Company\u2019s Press Release dated July 14, 2022.\n<\/p>\n

\nAbout MedX Health Corp.:<\/b>\n<\/p>\n

\nMedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy\u00ae on DermSecure\u00ae telemedicine platform, utilizing its SIAscopy\u00ae technology. SIAscopy\u00ae is also imbedded in its products SIAMETRICS\u00ae, SIMSYS\u00ae, and MoleMate\u00ae, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS\u00ae, SIMSYS\u00ae, and MoleMate\u00ae include hand-held devices that use patented technology utilizing light and its remittance to view suspicious moles and lesions up to 2mm beneath in a pain-free, non-invasive manner. Its patented software then creates real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformit\u00e9 Europ\u00e9enne for use in Canada, the U.S., Australia, New Zealand, the European Union, Brazil and Turkey. For more information, visit www.medxhealth.com<\/a>.\n<\/p>\n

\nNeither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.<\/i><\/b>\n<\/p>\n

\nThis Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.<\/i><\/b>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nBill Mitoulas, Investor Relations
\n
MedX Health Corp.
\n
bill@medxhealth.com<\/a>
+1-416-479-9547\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

MISSISSAUGA, Ontario–(BUSINESS WIRE)–$MDX #SkinCancer–MedX Health Corp. (\u201cMedX\u201d or the \u201cCompany\u201d) (TSXV: MDX) is pleased to announce that, in connection with the Private Placement (the \u201cFinancing\u201d), and further to the $250,000 first tranche closing of which was announced in its Press Release dated July 14, 2022, and its Press Release dated August 11, 2022 announcing application … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48166","6":"format-standard","7":"category-industry"},"yoast_head":"\nMedX Health Confirms Further Interim Closing and Application for Further Extension of Price Protection for Private Placement Convertible Loan Note Financing - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/medx-health-confirms-further-interim-closing-and-application-for-further-extension-of-price-protection-for-private-placement-convertible-loan-note-financing\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MedX Health Confirms Further Interim Closing and Application for Further Extension of Price Protection for Private Placement Convertible Loan Note Financing - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"MISSISSAUGA, Ontario–(BUSINESS WIRE)–$MDX #SkinCancer–MedX Health Corp. (\u201cMedX\u201d or the \u201cCompany\u201d) (TSXV: MDX) is pleased to announce that, in connection with the Private Placement (the \u201cFinancing\u201d), and further to the $250,000 first tranche closing of which was announced in its Press Release dated July 14, 2022, and its Press Release dated August 11, 2022 announcing application ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/medx-health-confirms-further-interim-closing-and-application-for-further-extension-of-price-protection-for-private-placement-convertible-loan-note-financing\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-09T13:01:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220909005112\/en\/1566590\/21\/MedX_Logo_copy.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-health-confirms-further-interim-closing-and-application-for-further-extension-of-price-protection-for-private-placement-convertible-loan-note-financing\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-health-confirms-further-interim-closing-and-application-for-further-extension-of-price-protection-for-private-placement-convertible-loan-note-financing\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"MedX Health Confirms Further Interim Closing and Application for Further Extension of Price Protection for Private Placement Convertible Loan Note Financing\",\"datePublished\":\"2022-09-09T13:01:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-health-confirms-further-interim-closing-and-application-for-further-extension-of-price-protection-for-private-placement-convertible-loan-note-financing\\\/\"},\"wordCount\":480,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-health-confirms-further-interim-closing-and-application-for-further-extension-of-price-protection-for-private-placement-convertible-loan-note-financing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220909005112\\\/en\\\/1566590\\\/21\\\/MedX_Logo_copy.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-health-confirms-further-interim-closing-and-application-for-further-extension-of-price-protection-for-private-placement-convertible-loan-note-financing\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-health-confirms-further-interim-closing-and-application-for-further-extension-of-price-protection-for-private-placement-convertible-loan-note-financing\\\/\",\"name\":\"MedX Health Confirms Further Interim Closing and Application for Further Extension of Price Protection for Private Placement Convertible Loan Note Financing - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-health-confirms-further-interim-closing-and-application-for-further-extension-of-price-protection-for-private-placement-convertible-loan-note-financing\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-health-confirms-further-interim-closing-and-application-for-further-extension-of-price-protection-for-private-placement-convertible-loan-note-financing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220909005112\\\/en\\\/1566590\\\/21\\\/MedX_Logo_copy.jpg\",\"datePublished\":\"2022-09-09T13:01:52+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-health-confirms-further-interim-closing-and-application-for-further-extension-of-price-protection-for-private-placement-convertible-loan-note-financing\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-health-confirms-further-interim-closing-and-application-for-further-extension-of-price-protection-for-private-placement-convertible-loan-note-financing\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-health-confirms-further-interim-closing-and-application-for-further-extension-of-price-protection-for-private-placement-convertible-loan-note-financing\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220909005112\\\/en\\\/1566590\\\/21\\\/MedX_Logo_copy.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220909005112\\\/en\\\/1566590\\\/21\\\/MedX_Logo_copy.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-health-confirms-further-interim-closing-and-application-for-further-extension-of-price-protection-for-private-placement-convertible-loan-note-financing\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MedX Health Confirms Further Interim Closing and Application for Further Extension of Price Protection for Private Placement Convertible Loan Note Financing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MedX Health Confirms Further Interim Closing and Application for Further Extension of Price Protection for Private Placement Convertible Loan Note Financing - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/medx-health-confirms-further-interim-closing-and-application-for-further-extension-of-price-protection-for-private-placement-convertible-loan-note-financing\/","og_locale":"en_US","og_type":"article","og_title":"MedX Health Confirms Further Interim Closing and Application for Further Extension of Price Protection for Private Placement Convertible Loan Note Financing - Pharma Trend","og_description":"MISSISSAUGA, Ontario–(BUSINESS WIRE)–$MDX #SkinCancer–MedX Health Corp. (\u201cMedX\u201d or the \u201cCompany\u201d) (TSXV: MDX) is pleased to announce that, in connection with the Private Placement (the \u201cFinancing\u201d), and further to the $250,000 first tranche closing of which was announced in its Press Release dated July 14, 2022, and its Press Release dated August 11, 2022 announcing application ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/medx-health-confirms-further-interim-closing-and-application-for-further-extension-of-price-protection-for-private-placement-convertible-loan-note-financing\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-09T13:01:52+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220909005112\/en\/1566590\/21\/MedX_Logo_copy.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/medx-health-confirms-further-interim-closing-and-application-for-further-extension-of-price-protection-for-private-placement-convertible-loan-note-financing\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/medx-health-confirms-further-interim-closing-and-application-for-further-extension-of-price-protection-for-private-placement-convertible-loan-note-financing\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"MedX Health Confirms Further Interim Closing and Application for Further Extension of Price Protection for Private Placement Convertible Loan Note Financing","datePublished":"2022-09-09T13:01:52+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/medx-health-confirms-further-interim-closing-and-application-for-further-extension-of-price-protection-for-private-placement-convertible-loan-note-financing\/"},"wordCount":480,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/medx-health-confirms-further-interim-closing-and-application-for-further-extension-of-price-protection-for-private-placement-convertible-loan-note-financing\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220909005112\/en\/1566590\/21\/MedX_Logo_copy.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/medx-health-confirms-further-interim-closing-and-application-for-further-extension-of-price-protection-for-private-placement-convertible-loan-note-financing\/","url":"https:\/\/pharma-trend.com\/en\/medx-health-confirms-further-interim-closing-and-application-for-further-extension-of-price-protection-for-private-placement-convertible-loan-note-financing\/","name":"MedX Health Confirms Further Interim Closing and Application for Further Extension of Price Protection for Private Placement Convertible Loan Note Financing - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/medx-health-confirms-further-interim-closing-and-application-for-further-extension-of-price-protection-for-private-placement-convertible-loan-note-financing\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/medx-health-confirms-further-interim-closing-and-application-for-further-extension-of-price-protection-for-private-placement-convertible-loan-note-financing\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220909005112\/en\/1566590\/21\/MedX_Logo_copy.jpg","datePublished":"2022-09-09T13:01:52+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/medx-health-confirms-further-interim-closing-and-application-for-further-extension-of-price-protection-for-private-placement-convertible-loan-note-financing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/medx-health-confirms-further-interim-closing-and-application-for-further-extension-of-price-protection-for-private-placement-convertible-loan-note-financing\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/medx-health-confirms-further-interim-closing-and-application-for-further-extension-of-price-protection-for-private-placement-convertible-loan-note-financing\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220909005112\/en\/1566590\/21\/MedX_Logo_copy.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220909005112\/en\/1566590\/21\/MedX_Logo_copy.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/medx-health-confirms-further-interim-closing-and-application-for-further-extension-of-price-protection-for-private-placement-convertible-loan-note-financing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"MedX Health Confirms Further Interim Closing and Application for Further Extension of Price Protection for Private Placement Convertible Loan Note Financing"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48166","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48166"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48166\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48166"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48166"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48166"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}